Coordinate Autophagy and mTOR Pathway Inhibition Enhances Cell Death in Melanoma
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway promotes melanoma tumor growth and survival while suppressing autophagy, a catabolic process through which cells collect and recycle cellular components to sustain energy homeostasis in starvation. Conversely, inhibitors of the PI3K/AKT/mTOR pathway, in particular the mTOR inhibitor temsirolimus (CCI-779), induce autophagy, which can promote tumor survival and thus, these agents potentially limit their own efficacy. We hypothesized that inhibition of autophagy in combination with mTOR inhibition would block this tumor survival mechanism and hence improve the cytotoxicity of mTOR inhibitors in melanoma. Here we found that melanoma cell lines of multiple genotypes exhibit high basal levels of autophagy. Knockdown of expression of the essential autophagy gene product ATG7 resulted in cell death, indicating that survival of melanoma cells is autophagy-dependent. We also found that the lysosomotropic agent and autophagy inhibitor hydroxychloroquine (HCQ) synergizes with CCI-779 and led to melanoma cell death via apoptosis. Combination treatment with CCI-779 and HCQ suppressed melanoma growth and induced cell death both in 3-dimensional (3D) spheroid cultures and in tumor xenografts. These data suggest that coordinate inhibition of the mTOR and autophagy pathways promotes apoptosis and could be a new therapeutic paradigm for the treatment of melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, high levels of autophagy in melanoma correlates with metastasis80, poor response to chemotherapy, and shorter overall survival78,80.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [78]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent work suggests that malignant melanomas have increased autophagic flux relative to benign nevi78–80.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [78]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Combined inhibition of autophagy and mTOR signaling enhances cell death78 and impairs metastasis88 in BRAFV600E mutant melanomas.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Autophagy in the Pathogenesis of Disease
Levine, B., & Kroemer, G. (2008) · Cell · doi:10.1016/j.cell.2007.12.018 · Cited by 7,069
LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.
Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T., Kominami, E., Ohsumi, Y., & Yoshimori, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.21.5720 · Cited by 6,605
Cui, C., Cui, J., Jin, F., Cui, Y., Li, R., Jiang, X., Tian, Y., Wang, K., Jiang, P., & Gao, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479571 · Cited by 5,203
Autophagy and Viruses: Adversaries or Allies?
Dong, X., & Levine, B. (2013) · Journal of Innate Immunity · doi:10.1159/000346388 · Cited by 4,430
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019 · cited 1×
“Among agents that interfere with PI3K/ AKT/mTOR signaling, inhibitors of mTOR are furthest in clinical development and have demonstrated efficacy in renal cell carcinomas as well as in patients with neuroendocrine tumors of pancreatic origin and in postmenopausal patients with hormone receptor positive breast cancer […”
BackgroundEverolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
The role of autophagy during the early neonatal starvation period
Kuma, A., Hatano, M., Matsui, M., Yamamoto, A., Nakaya, H., Yoshimori, T., Ohsumi, Y., Tokuhisa, T., & Mizushima, N. (2004) · Nature · doi:10.1038/nature03029 · Cited by 2,865 · cited 1×
“mammalian survival mechanism, highlighted by the failure of mice deficient in the essential autophagy gene atg5 to survive the neonatal starvation period [26].”
BackgroundEverolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · cited 1×
“Among agents that interfere with PI3K/ AKT/mTOR signaling, inhibitors of mTOR are furthest in clinical development and have demonstrated efficacy in renal cell carcinomas as well as in patients with neuroendocrine tumors of pancreatic origin and in postmenopausal patients with hormone receptor positive breast cancer […”
BackgroundRavikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347 · cited 1×
“Autophagy is induced by multiple anticancer agents [19,20], especially mTOR inhibitors [21,22], as a tumor survival-promoting mechanism.”
BackgroundHomeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice.
Komatsu, M., Waguri, S., Koike, M., Sou, Y.-S., Ueno, T., Hara, T., Mizushima, N., Iwata, J.-I., Ezaki, J., Murata, S., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.035 · Cited by 2,124 · cited 1×
“Under normal conditions, autophagy is active at low levels to remove the occasional damaged organelle or unfolded protein to prevent their toxic accumulation [27,28].”
BackgroundNutrient-dependent mTORC1 Association with the ULK1–Atg13–FIP200 Complex Required for Autophagy
Hosokawa, N., Hara, T., Kaizuka, T., Kishi, C., Takamura, A., Miura, Y., Iemura, S.-I., Natsume, T., Takehana, K., Yamada, N., et al. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-12-1248 · Cited by 2,076 · cited 1×
“This frees ULK1/2 to activate FIP200, a protein crucial for autophagosome formation, and initiate autophagy [33,34,35,36].”
BackgroundULK-Atg13-FIP200 Complexes Mediate mTOR Signaling to the Autophagy Machinery
Jung, C. H., Jun, C. B., Ro, S.-H., Kim, Y.-M., Otto, N. M., Cao, J., Kundu, M., & Kim, D.-H. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-12-1249 · Cited by 2,025 · cited 1×
“This frees ULK1/2 to activate FIP200, a protein crucial for autophagosome formation, and initiate autophagy [33,34,35,36].”
BackgroundAutophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis
Degenhardt, K., Mathew, R., Beaudoin, B., Bray, K., Anderson, D., Chen, G., Mukherjee, C., Shi, Y., Gélinas, C., Fan, Y., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.001 · Cited by 2,011
Self-citationRabinowitz, J. D., & White, E. (2010) · Science · doi:10.1126/science.1193497 · Cited by 1,982
Self-citationMathew, R., Karantza-Wadsworth, V., & White, E. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2254 · Cited by 1,798 · cited 1×
“Autophagy is also induced in insufficiently vascularized tumors, localized preferentially to hypoxic tumor regions, where deficiency in autophagy compromises tumor cell survival [30,31,32].”
BackgroundSelf-citationAutophagy Suppresses Tumorigenesis through Elimination of p62
Mathew, R., Karp, C. M., Beaudoin, B., Vuong, N., Chen, G., Chen, H.-Y., Bray, K., Reddy, A., Bhanot, G., Gelinas, C., et al. (2009) · Cell · doi:10.1016/j.cell.2009.03.048 · Cited by 1,719
Self-citationDeconvoluting the context-dependent role for autophagy in cancer
White, E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3262 · Cited by 1,704
Self-citationPancreatic cancers require autophagy for tumor growth
Yang, S., Wang, X., Contino, G., Liesa, M., Sahin, E., Ying, H., Bause, A., Li, Y., Stommel, J. M., Dell'Antonio, G., et al. (2011) · Genes & Development · doi:10.1101/gad.2016111 · Cited by 1,498 · cited 6×
“This approach has been the subject of multiple investigations [38,39,40,41,42,43,44,45] [46]which indicate that addition of the antimalarial choloroquine (CQ) promotes tumor cell death in preclinical models.”
BackgroundResultInfluentialGrowth factor regulation of autophagy and cell survival in the absence of apoptosis
Lum, J. J., Bauer, D. E., Kong, M., Harris, M. H., Li, C., Lindsten, T., & Thompson, C. B. (2005) · Cell · doi:10.1016/j.cell.2004.11.046 · Cited by 1,487 · cited 1×
“Under stressful conditions such as nutrient deprivation, hypoxia, or other sources of cellular stress such as chemotherapy or targeted therapies, autophagy is dramatically induced as a protective mechanism to maintain homeostasis and viability [29].”
BackgroundULK1·ATG13·FIP200 Complex Mediates mTOR Signaling and Is Essential for Autophagy
Ganley, I. G., Lam, D. H., Wang, J., Ding, X., Chen, S., & Jiang, X. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900573200 · Cited by 1,447
Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
Guo, J. Y., Chen, H.-Y., Mathew, R., Fan, J., Strohecker, A. M., Karsli-Uzunbas, G., Kamphorst, J. J., Chen, G., Lemons, J. M. S., Karantza, V., et al. (2011) · Genes & Development · doi:10.1101/gad.2016311 · Cited by 1,323 · cited 7×
“This approach has been the subject of multiple investigations [38,39,40,41,42,43,44,45] [46]which indicate that addition of the antimalarial choloroquine (CQ) promotes tumor cell death in preclinical models.”
BackgroundMethodResultSelf-citationThe Double-Edged Sword of Autophagy Modulation in Cancer
White, E., & DiPaola, R. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5023 · Cited by 1,138
Self-citationAutophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma
Amaravadi, R. K., Yu, D., Lum, J. J., Bui, T., Christophorou, M. A., Evan, G. I., Thomas-Tikhonenko, A., & Thompson, C. B. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28833 · Cited by 1,137
Principles and Current Strategies for Targeting Autophagy for Cancer Treatment
Amaravadi, R. K., Lippincott-Schwartz, J., Yin, X.-M., Weiss, W. A., Takebe, N., Timmer, W., DiPaola, R. S., Lotze, M. T., & White, E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2634 · Cited by 897
Self-citationManagement of Cutaneous Melanoma
Tsao, H., Atkins, M. B., & Sober, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041245 · Cited by 855
Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis
Karantza-Wadsworth, V., Patel, S., Kravchuk, O., Chen, G., Mathew, R., Jin, S., & White, E. (2007) · Genes & Development · doi:10.1101/gad.1565707 · Cited by 841
Self-citationSotelo, J., Briceño, E., & López-González, M. A. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-5-200603070-00008 · Cited by 505
Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation
Lock, R., Roy, S., Kenific, C. M., Su, J. S., Salas, E., Ronen, S. M., & Debnath, J. (2011) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-06-0500 · Cited by 467
Smalley, K. S. M., Haass, N. K., Brafford, P. A., Lioni, M., Flaherty, K. T., & Herlyn, M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0084 · Cited by 463
Elgendy, M., Sheridan, C., Brumatti, G., & Martin, S. J. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.02.009 · Cited by 426 · cited 1×
“Studies from our group and others have shown that aggressive cancers such as those with activating mutations in Ras have high basal autophagy, suggesting that the genetic events that produce cancer may be inherently stressful [38,46,68,69].”
BackgroundRangwala, R., Chang, Y. C., Hu, J., Algazy, K. M., Evans, T. L., Fecher, L. A., Schuchter, L. M., Torigian, D. A., Panosian, J. T., Troxel, A. B., et al. (2014) · Autophagy · doi:10.4161/auto.29119 · Cited by 424
McAfee, Q., Zhang, Z., Samanta, A., Levi, S. M., Ma, X.-H., Piao, S., Lynch, J. P., Uehara, T., Sepulveda, A. R., Davis, L. E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118193109 · Cited by 422
An Atg1/Atg13 Complex with Multiple Roles in TOR-mediated Autophagy Regulation
Chang, Y.-Y., & Neufeld, T. P. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-12-1250 · Cited by 417
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents
Degtyarev, M., De Mazière, A., Orr, C., Lin, J., Lee, B. B., Tien, J. Y., Prior, W. W., van Dijk, S., Wu, H., Gray, D. C., et al. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200801099 · Cited by 366
Genome-scale loss-of-function screening with a lentiviral RNAi library
Root, D. E., Hacohen, N., Hahn, W. C., Lander, E. S., & Sabatini, D. M. (2006) · Nature Methods · doi:10.1038/nmeth924 · Cited by 357
Sato, K., Tsuchihara, K., Fujii, S., Sugiyama, M., Goya, T., Atomi, Y., Ueno, T., Ochiai, A., & Esumi, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1462 · Cited by 352
Lazova, R., Camp, R. L., Klump, V., Siddiqui, S. F., Amaravadi, R. K., & Pawelek, J. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1282 · Cited by 305 · cited 2×
“High levels of autophagy are a common feature of multiple tumor types and an independent predictor of poor prognosis in colorectal, pancreatic, and gastrointestinal tumors as well as melanoma [48,55,56,57].”
BackgroundAutophagy is activated in pancreatic cancer cells and correlates with poor patient outcome
Fujii, S., Mitsunaga, S., Yamazaki, M., Hasebe, T., Ishii, G., Kojima, M., Kinoshita, T., Ueno, T., Esumi, H., & Ochiai, A. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00893.x · Cited by 279
Maclean, K. H., Dorsey, F. C., Cleveland, J. L., & Kastan, M. B. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33700 · Cited by 272
Meier, F. (2005) · Frontiers in Bioscience · doi:10.2741/1755 · Cited by 267
Curcumin inhibits the mammalian target of rapamycin‐mediated signaling pathways in cancer cells
Beevers, C. S., Li, F., Liu, L., & Huang, S. (2006) · International Journal of Cancer · doi:10.1002/ijc.21932 · Cited by 256
Toward a Molecular Classification of Melanoma
Fecher, L. A., Cummings, S. D., Keefe, M. J., & Alani, R. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0442 · Cited by 252
Hydroxychloroquine concentration–response relationships in patients with rheumatoid arthritis
Munster, T., Gibbs, J. P., Shen, D., Baethge, B. A., Botstein, G. R., Caldwell, J., Dietz, F., Ettlinger, R., Golden, H. E., Lindsley, H., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10307 · Cited by 249
Sheen, J.-H., Zoncu, R., Kim, D., & Sabatini, D. M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.012 · Cited by 239
Ma, X.-H., Piao, S., Wang, D., Mcafee, Q. W., Nathanson, K. L., Lum, J. J., Li, L. Z., & Amaravadi, R. K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2372 · Cited by 234
CCI‐779 in metastatic melanoma: A Phase II trial of the California Cancer Consortium
Margolin, K., Longmate, J., Baratta, T., Synold, T., Christensen, S., Weber, J., Gajewski, T., Quirt, I., & Doroshow, J. H. (2005) · Cancer · doi:10.1002/cncr.21265 · Cited by 227
Autophagy inhibition enhances vorinostat‐induced apoptosis via ubiquitinated protein accumulation
Carew, J. S., Medina, E. C., Esquivel II, J. A., Mahalingam, D., Swords, R., Kelly, K., Zhang, H., Huang, P., Mita, A. C., Mita, M. M., et al. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00832.x · Cited by 219
Tang, Y., Chen, Y., Jiang, H., & Nie, D. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2010.117 · Cited by 201
Qadir, M. A., Kwok, B., Dragowska, W. H., To, K. H., Le, D., Bally, M. B., & Gorski, S. M. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9873-4 · Cited by 201
LC3, an autophagosome marker, is highly expressed in gastrointestinal cancers
Yoshioka (1992) · International Journal of Oncology · doi:10.3892/ijo_00000028 · Cited by 192
Autophagy Is a Protective Mechanism for Human Melanoma Cells under Acidic Stress
Marino, M. L., Pellegrini, P., Di Lernia, G., Djavaheri-Mergny, M., Brnjic, S., Zhang, X., Hägg, M., Linder, S., Fais, S., Codogno, P., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.339127 · Cited by 184
Marino, M. L., Fais, S., Djavaheri-Mergny, M., Villa, A., Meschini, S., Lozupone, F., Venturi, G., Della Mina, P., Pattingre, S., Rivoltini, L., et al. (2010) · Cell Death & Disease · doi:10.1038/cddis.2010.67 · Cited by 169
Autophagy Suppresses RIP Kinase-Dependent Necrosis Enabling Survival to mTOR Inhibition
Bray, K., Mathew, R., Lau, A., Kamphorst, J. J., Fan, J., Chen, J., Chen, H.-Y., Ghavami, A., Stein, M., DiPaola, R. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041831 · Cited by 155
Self-citationYazbeck, V. Y., Buglio, D., Georgakis, G. V., Li, Y., Iwado, E., Romaguera, J. E., Kondo, S., & Younes, A. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2007.12.008 · Cited by 145
Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions
Miracco, C., Cevenini, G., Franchi, A., Luzi, P., Cosci, E., Mourmouras, V., Monciatti, I., Mannucci, S., Biagioli, M., Toscano, M., et al. (2010) · Human Pathology · doi:10.1016/j.humpath.2009.09.004 · Cited by 139 · cited 1×
“These results are consistent with other reports, albeit using different techniques, which indicate that the degree of baseline autophagy among human melanomas is heterogeneous [49,58].”
ResultTargeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors
Marone, R., Erhart, D., Mertz, A. C., Bohnacker, T., Schnell, C., Cmiljanovic, V., Stauffer, F., Garcia-Echeverria, C., Giese, B., Maira, S.-M., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0366 · Cited by 121
A Melanoma Molecular Disease Model
Vidwans, S. J., Flaherty, K. T., Fisher, D. E., Tenenbaum, J. M., Travers, M., & Shrager, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018257 · Cited by 106
Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies
Mehnert, J. M., & Kluger, H. M. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0249-5 · Cited by 97
Self-citationVerschooten, L., Barrette, K., Van Kelst, S., Rubio Romero, N., Proby, C., De Vos, R., Agostinis, P., & Garmyn, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048264 · Cited by 89 · cited 1×
“This is similar to our previously published findings in renal cell carcinoma models [23] and reflective of reports which indicate that the addition of chloroquine analogs sensitizes tumor cells to anticancer treatments [39,40,41,44,45,62,63].”
ResultMargolin, K. A., Moon, J., Flaherty, L. E., Lao, C. D., Akerley, W., Othus, M. K. D., Sosman, J. A., Kirkwood, J. M., & Sondak, V. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2488 · Cited by 89
Targeting Intracellular Signaling Pathways as a Novel Strategy in Melanoma Therapeutics
Smalley, K. S. M., & Herlyn, M. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1339.005 · Cited by 88
Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens
Ladoire, S., Chaba, K., Martins, I., Sukkurwala, A. Q., Adjemian, S., Michaud, M., Poirier-Colame, V., Andreiuolo, F., Galluzzi, L., White, E., et al. (2012) · Autophagy · doi:10.4161/auto.20353 · Cited by 79
Self-citationPhosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma
Aziz, S. A., Davies, M. A., Pick, E., Zito, C. R., Jilaveanu, L. B., Camp, R. L., Rimm, D. L., Kluger, Y., & Kluger, H. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2768 · Cited by 79
Hui, B., Shi, Y., Ding, Z., Zhou, J., Gu, C., Peng, Y., Yang, H., Liu, W., Shi, G., & Fan, J. (2012) · Cancer · doi:10.1002/cncr.27586 · Cited by 74
Counteracting Autophagy Overcomes Resistance to Everolimus in Mantle Cell Lymphoma
Rosich, L., Xargay-Torrent, S., López-Guerra, M., Campo, E., Colomer, D., & Roué, G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0351 · Cited by 70
Oncogenic B-RAF Signaling in Melanoma Impairs the Therapeutic Advantage of Autophagy Inhibition
Armstrong, J. L., Corazzari, M., Martin, S., Pagliarini, V., Falasca, L., Hill, D. S., Ellis, N., Al Sabah, S., Redfern, C. P. F., Fimia, G. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3003 · Cited by 65 · cited 2×
“Indeed, existing reports of knockdown of the essential autophagy components Atg5 or Atg7 in the literature suggest that this approach results in increased cell death in different melanoma cell lines, although additional metabolic stressors may be required [59,60,61].”
BackgroundWerzowa, J. M., Koehrer, S., Strommer, S., Cejka, D., Fuereder, T., Zebedin, E., & Wacheck, V. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.327 · Cited by 55
Autophagy and Akt promote survival in glioma
Fan, Q.-W., & Weiss, W. A. (2011) · Autophagy · doi:10.4161/auto.7.5.14779 · Cited by 53
Ghadimi, M. P., Lopez, G., Torres, K. E., Belousov, R., Young, E. D., Liu, J., Savannah, K. J. B., Hoffman, A., Lusby, K., Lazar, A. J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0015 · Cited by 49
mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics
Pópulo, H., Soares, P., Faustino, A., Rocha, A. S., Silva, P., Azevedo, F., & Lopes, J. M. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00796.x · Cited by 47
Algazy, K. M., Schuchter, L. M., DeMichele, A. M., Vaughn, D. J., Torigian, D. A., Chang, Y. C., Redlinger, M., Davis, L. E., O'Dwyer, P. J., & Amaravadi, R. K. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-4500 · Cited by 3
Rosich, L., Xargay‐Torrent, S., López‐Guerra, M., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-11-c72 · Cited by 1
Cited by
The role for autophagy in cancer
White, E. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73941 · Cited by 1,332
Self-citationTargeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
Recent insights into the function of autophagy in cancer
Amaravadi, R., Kimmelman, A. C., & White, E. (2016) · Genes & Development · doi:10.1101/gad.287524.116 · Cited by 813
Self-citationAutophagy, Metabolism, and Cancer
White, E., Mehnert, J. M., & Chan, C. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0490 · Cited by 664
Self-citationEmran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F. R., Ahmed, H., Rahman, N., Nainu, F., Wahyudin, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891652 · Cited by 606
Metadata
- Authors
- Xie, X., White, E. P., & Mehnert, J. M.
- Affiliations
- Rutgers Cancer Institute (US)
- Rutgers, The State University of New Jersey (US)
- Corresponding author
- White, Eileen P.
- Mehnert, Janice M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-01-30
- Volume
- 8
- Issue
- 1
- Pages
- e55096
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3559441
- OpenAlex
- W2033843689
- Cited by
- 150
- References
- 77
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 8 · 2023: 8 · 2022: 13 · 2021: 12 · 2020: 4 · 2019: 16 · 2018: 10 · 2017: 13 · 2016: 18 · 2015: 17 · 2014: 19 · 2013: 10
- FWCI
- 15.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- V Foundation for Cancer Research
- University of Arizona Cancer Center
- Rutgers Cancer Institute of New Jersey
- National Cancer Institute (R01CA130893, R01CA163591)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Calcium signaling and nucleotide metabolism
- Keywords
- melanoma, autophagy, mTOR inhibition, temsirolimus, PI3K/AKT/mTOR pathway, hydroxychloroquine, ATG7, apoptosis, combination therapy, tumor growth inhibition, tumor xenografts, 3D spheroid culture
- MeSH terms
- Autophagy-Related Protein 7, Allosteric Regulation, Animals, Autophagy, Cell Transformation, Neoplastic, Drug Synergism, Humans, Hydroxychloroquine, Male, Melanoma, Mice, Nude, Signal Transduction, Sirolimus, Ubiquitin-Activating Enzymes, Cell Line, Tumor, Cell Proliferation, Mice, Gene Knockdown Techniques, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.